A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics

Non-muscle invasive bladder cancer (NMIBC) has a high rate of postoperative recurrence and the efficacy of existing clinical prediction models is limited. This study aimed to combine multiparametric magnetic resonance imaging (mp-MRI) radiomic features with clinical characteristics to construct a machine learning model for accurately predicting the risk of recurrence within 2 years postoperatively in NMIBC patients. Retrospectively including 183 NMIBC patients (57 in the recurrence group, 126 in the non-recurrence group), radiomic features from mp-MRI imaging (T2W, ADC, and enhancement sequences) were extracted. Through LASSO selection, 4 key imaging features (MajorAxisLength, SZNN, S/V, Skewness) and 6 clinical features based on the EAU 2021 risk stratification were identified to constitute the clinical-imaging dataset. Through comparison with 10 machine learning models, Support Vector Machine (SVM) performed the best (training set AUC = 0.973, validation set AUC = 0.891), with external independent validation (108 cases) showing AUCs of 0.88 and 0.87, demonstrating good generalization ability. A bar chart integrating radiomics score (Rad-Score) with clinical features provides an intuitive prognostic tool. The study indicates that the clinical-imaging radiomics model based on SVM significantly enhances the efficacy of NMIBC recurrence prediction, addressing the shortcomings of traditional risk assessment and offering a reliable basis for personalized postoperative management. Study limitations include the retrospective design and the absence of molecular biomarkers, necessitating future multicenter prospective validation.

Authors

Institutions

Publication Details

Journal
BMC Cancer
Published
2025-10-02
DOI
https://doi.org/10.1186/s12885-025-14753-1
Citations
2
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
4.01
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics

Z. Li, Jieming Zuo, Shi Fu, Zhenhui Li et al.
2 citations
BMC Cancer
Bladder and Urothelial Cancer Treatments
4.01
article

A study on predicting recurrence of non-muscle-invasive bladder cancer within 2 years using mp-MRI radiomics

Z. Li, Jieming Zuo, Shi Fu, Zhenhui Li, Bo Chen, Yueting Zhou, Haifeng Wang, Junhao Chen
article en
2 citations

Abstract

Non-muscle invasive bladder cancer (NMIBC) has a high rate of postoperative recurrence and the efficacy of existing clinical prediction models is limited. This study aimed to combine multiparametric magnetic resonance imaging (mp-MRI) radiomic features with clinical characteristics to construct a machine learning model for accurately predicting the risk of recurrence within 2 years postoperatively in NMIBC patients. Retrospectively including 183 NMIBC patients (57 in the recurrence group, 126 in the non-recurrence group), radiomic features from mp-MRI imaging (T2W, ADC, and enhancement sequences) were extracted. Through LASSO selection, 4 key imaging features (MajorAxisLength, SZNN, S/V, Skewness) and 6 clinical features based on the EAU 2021 risk stratification were identified to constitute the clinical-imaging dataset. Through comparison with 10 machine learning models, Support Vector Machine (SVM) performed the best (training set AUC = 0.973, validation set AUC = 0.891), with external independent validation (108 cases) showing AUCs of 0.88 and 0.87, demonstrating good generalization ability. A bar chart integrating radiomics score (Rad-Score) with clinical features provides an intuitive prognostic tool. The study indicates that the clinical-imaging radiomics model based on SVM significantly enhances the efficacy of NMIBC recurrence prediction, addressing the shortcomings of traditional risk assessment and offering a reliable basis for personalized postoperative management. Study limitations include the retrospective design and the absence of molecular biomarkers, necessitating future multicenter prospective validation.

BMC CancerVol. 25(1)
Kunming Medical University (CN), First People's Hospital of Yunnan Province (CN)
Openalex Percentile: Top 6%
Bladder and Urothelial Cancer Treatments
4.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.